Reuters Health Information (2005-10-05): EU OKs briefer Schering-Plough hepatitis C therapy
EU OKs briefer Schering-Plough hepatitis C therapy
Last Updated: 2005-10-05 14:33:39 -0400 (Reuters Health)
NEW YORK (Reuters) - Schering-Plough Corp. on Wednesday
said European regulators approved a 24-week course of treatment with
its combination therapy for some patients infected with the most common
form of hepatitis C, rather than the standard 48-week regimen.
The company said the European Commission approved the shorter
treatment for a "subgroup" of patients with low bloodstream levels of
the genotype 1 form of the virus, whose virus levels then fall to
undetectable levels during the first four weeks of treatment.
"This is the only treatment regimen approved in the European Union
for a 24-week course of therapy in certain genotype 1 patients," the
Kenilworth, New Jersey-based company said in a release.